{"version":"1.0","provider_name":"Pharma Trend","provider_url":"https:\/\/pharma-trend.com\/en","author_name":"Business Wire","author_url":"https:\/\/pharma-trend.com\/en\/author\/business\/","title":"Antibe Extends Early Warrant Exercise Incentive Program - Pharma Trend","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"g5fhJH6S2e\"><a href=\"https:\/\/pharma-trend.com\/en\/antibe-extends-early-warrant-exercise-incentive-program\/\">Antibe Extends Early Warrant Exercise Incentive Program<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/pharma-trend.com\/en\/antibe-extends-early-warrant-exercise-incentive-program\/embed\/#?secret=g5fhJH6S2e\" width=\"600\" height=\"338\" title=\"&#8220;Antibe Extends Early Warrant Exercise Incentive Program&#8221; &#8212; Pharma Trend\" data-secret=\"g5fhJH6S2e\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/pharma-trend.com\/en\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","description":"TORONTO&#8211;(BUSINESS WIRE)&#8211;$ATBPF&#8211;Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is extending the Early Warrant Exercise Incentive Program (\u201cEarly Warrant Exercise Program\u201d) for its 6.4 million outstanding and unlisted share purchase warrants having an exercise price of $1.50 (\u201cExercise Price\u201d) ... [Read more...]","thumbnail_url":"https:\/\/mms.businesswire.com\/media\/20240201407055\/en\/718346\/21\/ANTIBE-logo-RGB.jpg"}